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Introduction {#s1}
============

G protein-coupled receptors (GPCRs) represent the largest family of membranous signaling molecules and are characterized structurally by a highly conserved seven-transmembrane domain motif ([@CIT0003]; [@CIT0014]). GPCRs recognize an incredible variety of ligands, including odorants, photons, neurotransmitters, lipids, hormones, peptides, and other small molecules, and regulate intracellular response to adapt to the ever-changing environment ([@CIT0003]). Upon agonist activation, GPCRs undergo prototypical structural re-arrangements facilitating the interaction with a family of canonical heterotrimeric G-proteins (e.g., Gq, Gs, Gi, and G12/13) and G protein-independent signaling molecules ([@CIT0003]). GPCR signaling modulates virtually every known physiological response ([@CIT0003])

To control GPCR signaling for neuropsychopharmacological therapeutics, "selective" agonists or antagonists are typically developed ([@CIT0005]; [@CIT0014]). However, because most neuronal cells express multiple GPCRs and because most GPCRs are expressed in multiple tissues ([@CIT0017]), it is essentially impossible to regulate a specific GPCR-signaling pathway in a selective cell population by known pharmacological approaches. Additionally, the presence of endogenous receptor ligands and the lack of true specificity of pharmacological probes for GPCRs further confound the neuropsychopharmacological approach. To overcome these inherent problems associated with GPCR therapeutic approaches, the past two decades have seen a number of chemical-genetic approaches designed to control GPCR signaling *in vivo* (see [@CIT0505], for recent review). Although the 'first generation' chemogenetic tools were useful from a heuristic perspective, they were not widely adapted (see [@CIT0505], for review).

DREADD: A Useful and Robust Chemogenetic Platform {#s2}
=================================================

We adopted a novel strategy to discover useful chemogenetic tools utilizing directed molecular evolution in yeast. We were able to eventually evolve human muscarinic receptors to be activated by nM concentrations of the pharmacologically inert clozapine metabolite clozapine-N-oxide (CNO) and to simultaneously be insensitive to the native ligand acetylcholine ([@CIT0004]). Importantly, the engineered receptors which we dubbed DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) had minimal constitutive activity *in vitro* ([@CIT0004]) and *in vivo*, even when expressed at high levels in neurons ([@CIT0002]; [@CIT0021]).

Since the initial description of DREADD technology ([@CIT0004]), three DREADDs have been mostly commonly used in the neurosciences: hM3Dq, which is coupled to Gαq signaling and induces firing of neurons ([@CIT0002]); hM4Di, which is coupled to Gαi signaling and mediates neuronal ([@CIT0004]) and synaptic silencing ([@CIT0018]); and rM3Ds, which is coupled to Gαs signaling and which modulates neuronal activity ([@CIT0501]).

A schematic diagram for the application of DREADD technology is shown in [Figure 1](#F1){ref-type="fig"}. The typical strategy for using DREADD technology to gain remote control over neuronal signaling is quite simple and is as follows (see [Figure 1](#F1){ref-type="fig"} for diagram of ways of expressing DREADDs):

![Schematic diagram for the application of DREADD technology *in vivo*. (A) Two types of DREADD transgenic mouse models have been developed: cre-dependent and tet-dependent. DREADDs can be expressed in genetically defined cell populations after crossing with cre- or tet-off driver mouse lines. (B) Two types of DREADDs viruses were developed: cre-dependent and cre-independent. In the cre-dependent system, virus containing double-floxed inverted DREADDs are microinfused into the appropriate brain region in mice which express cell-type specific Cre drivers. DREADDs are flipped into the correct orientation and expressed after cre-mediated recombination to achieve very precise cell-type specific expression.](ijnppy_pyu007_f0001){#F1}

-   Express the DREADD in the cell-type of interest via either transgenic or viral technology

    -   For virally-mediated transduction wait 2--3 weeks for expression

-   Administer CNO either via parenteral or oral administration

-   Within a few minutes of CNO administration, the effect due to activation (via hM3Dq), inhibition (via hM4Di), or modulation (via GsD) of neuronal signaling occurs

-   Monitor behavior and/or neuronal firing in freely-moving animals

-   The effects of CNO will be negligible in animals which do not express DREADDs and profound in animals expressing DREADDs

Widespread Adoption of DREADD Technology {#s3}
========================================

DREADDs have been successfully demonstrated to control individual GPCR signaling in many *in vivo* studies from yeast, drosophila, mice, rats, and---perhaps in the near future---primates ([@CIT0008]) and, as of August 2014, more than 500 publications have cited DREADD technology. In the central nervous system (CNS), DREADDs have been shown to control neuronal activities in a variety of neurons, including glutamatergic ([@CIT0002]; [@CIT0021]), serotonergic ([@CIT0016]), dopaminergic ([@CIT0007]), and GABAergic neurons ([@CIT0011]), to name but a few. DREADDs have also been used to control glial cell activity to modulate the autonomic nervous system ([@CIT0001]). In periphery, DREADDs have been used to control GPCR signaling in pancreatic beta-cells ([@CIT0009]), hepatocytes ([@CIT0013]), and breast cancer cells ([@CIT0020]). As these applications have been reviewed recently we will not comment on them further here ([@CIT0019]).

Recent Advances in the DREADD Toolkit and DREADD Resources {#s4}
==========================================================

Currently, a substantial collection of DREADD-based tools is available to control GPCR signaling *in vivo* (see [Table 1](#T1){ref-type="table"}). Three DREADD transgenic mouse lines created by the Roth lab can now be obtained from Jackson Labs ([Table 1](#T1){ref-type="table"}). Cre-dependent hM3Dq and hM4Di transgenic mice are in the process of validation in the Roth lab and will be made available soon to provide cell-type specific transgenic control of DREADD expression as outlined in [Figure 1](#F1){ref-type="fig"}. Tissue-specific and cell type--specific expression of DREADDs can also be achieved by viral delivery ([@CIT0012]; [@CIT0019]). For many uses viral delivery is time-saving and yields a more precisely controlled DREADD expression. A variety of viral vectors---Cre-dependent or -independent---are listed in [Table 1](#T1){ref-type="table"} and the majority of them can be obtained from UNC viral core facility ([http://www.med.unc.edu/genetherapy/vectorcore/research-grade/ in-stock-aav-vectors/roth](http://www.med.unc.edu/genetherapy/vectorcore/research-grade/ in-stock-aav-vectors/roth)). Current DREADD-based plasmids are available from ADDGENE (<http://www.addgene.org/Bryan_Roth/>) and as a service to DREADD users a blog is updated frequently (<http://chemogenetic.blogspot.com/>).

###### 

Summary of Toolkit of DREADDs Technology

  Expression system   Subtype of DREADDs   Vector information                                   Control system                 Source                                                  Publication
  ------------------- -------------------- ---------------------------------------------------- ------------------------------ ------------------------------------------------------- ---------------------------
  Transgenic mice     hM3Dq                TRE-HA-hM3Dq                                         Tet off                        Available at Jackson Labs                               Alexander et al. (2009)
                                           LoxP-STOP-LoxP- HA-hM3Dq-PTA- mCitrine               Cre-LoxP                       Roth's lab (In validation)                              
                                           RIPII-hM3Dq                                          Insulin promoter II            Wess's lab                                              Guettier et al. (2009)
                                           C-fos-hM3Dq                                          C-fos promoter                 Mayford's lab                                           Garner et al. (2012)
                      hM4Di                TRE-HA-hM4Di                                         Tet off                        Available at Jackson Labs                               Zhu et al. (2014)
                                           LoxP-STOP-LoxP-HA- hM4Di-PTA-mCitrine                Cre-LoxP                       Roth's lab (In validation)                              
                                           CAG-FRT-STOP-FRT- LoxP-mCherry-STOP- loxP-HA-hM4Di   Cre-LoxP and FLP-FRT           Dymecki's lab                                           Ray et al. (2011)
                      rM3Ds                Adora2A-rM3Ds                                        Adora2A promoter               Available at Jackson Labs                               Farrell et al. (2013)
                                           RIPII-rM3Ds                                          Insulin promoter II            Wess's lab                                              Guettier et al. (2009)
  AAV virus           hM3Dq                HA-hM3Dq-IRES- mCitrine                              hSyn, CaMKIIa, GFAP promoter   UNC Viral Vector Core; plasmids available via ADDGENE   
                                           HA-hM3Dq- mCherry                                    hSyn, CaMKIIa, GFAP promoter   UNC Viral Vector Core; plasmids available via ADDGENE   
                                           hSyn-DIO-hM3Dq- mCherry                              Cre-LoxP                       UNC Viral Vector Core; plasmids available via ADDGENE   Urban and Roth (in press)
                      hM4Di                HA-hM4Di-IRES- mCitrine                              hSyn, CaMKIIa, GFAP promoter   UNC Viral Vector Core; plasmids available via ADDGENE   
                                           HA-hM4Di- mCherry                                    hSyn, CaMKIIa, GFAP promoter   UNC Viral Vector Core; plasmids available via ADDGENE   Zhu et al. (2014)
                                           hSyn-DIO-hM4Di- mCherry                              Cre-LoxP                       UNC Viral Vector Core; plasmids available via ADDGENE   
                      rM3Ds                HA-rM3Ds-IRES- mCitrine                              CaMKIIa, GFAP promoter         UNC Viral Vector Core; plasmids available via ADDGENE   
                                           hSyn-DIO-rM3Ds- mCherry                              Cre-LoxP                       UNC Viral Vector Core; plasmids available via ADDGENE   
  Lentivirus          hM3Dq                hM3Dq-mCherry                                        CMV promoter                   Available directly from Roth lab                        
                                           CMV-DIO-hM3Dq- mCherry                               Cre-LoxP                       Available directly from Roth lab                        
                      hM4Di                hM3Dq-mCherry                                        CMV promoter                   Available directly from Roth lab                        
                                           CMV-DIO-hM3Dq- mCherry                               Cre-LoxP                       Available directly from Roth lab                        
  HSV virus           hM4Di                ENK-hM4Di                                            Enk promoter                   Unknown availability                                    Ferguson et al. (2011)
                                           DYN-hM4Di                                            Dyn promoter                   Unknown availability                                    Ferguson et al. (2011)
  CAV2 virus          hM3Dq                hSyn-DIO-rM3Ds- mCherry                              Cre-LoxP                       Unknown availability                                    Boender et al. (2014)

We continue to develop new chemogenetic tools and soon will be describing those which afford bidirectional control of GPCR signaling in same-cell population via different synthetic ligands. In the meantime, new derivatives of DREADDs have been developed by others which are likely to be quite useful. Thus, for example, an arrestin-biased DREADD was generated ([@CIT0015]) and an axonal selective hM4D-neurexin variant was developed as a presynaptic silencer ([@CIT0018]).

Future Directions for DREADD Technology {#s5}
=======================================

The GPCR superfamily continues to be one of the major targets for drug discovery, although CNS drug discovery remains slow and risky ([@CIT0014]). Indeed, less than 5% of CNS drugs entering Phase I clinical trials are eventually approved by the FDA, and many GPCR-targeted drugs fail in Phase II and III clinical trials due to lack of clinical efficiency ([@CIT0006]). This raises the questions as to whether current animal models really recapitulate the physiological/pathological condition seen in human disease and whether pharmacological intervention of disease-related GPCR targets can ultimately deliver the desired therapeutic response. We suggest that DREADDs may represent a new "pre-evaluation" approach for GPCR drug discovery. For example, we can pre-evaluate whether pharmacological intervention of a given GPCR-signaling process by DREADD achieves the desired therapeutic response before starting a long and costly drug discovery process ([Figure 2](#F2){ref-type="fig"}).

![DREADDs represent a chemogenetic tool to modulate GPCR signaling *in vivo*. (A) Introducing two mutations in transmenbrane III and V of muscarinic receptors which create DREADDs receptors that can precisely control the Gq-, Gi-, or Gs-signaling pathways. (B) DREADDs technology has been successfully applied in β-cells, astrocytes, and a variety of neurons to control GPCR signaling *in vivo*. (C) DREADDs technology has a great potential to be used in drug discovery, gene therapy, and tissue engineering.](ijnppy_pyu007_f0002){#F2}

DREADDs may also represent a novel approach for combining gene therapy, tissue engineering, and synthetic biology. Indeed, in an important recent study [@CIT0007] demonstrated robust and bidirectional remote control of DREADD-expressing dopaminergic neurons, which induced from iPSCs (Induced pluripotent stem cells), and were able to markedly enhance the beneficial effects in a mouse model of Parkinson's Disease. This represents the first demonstration of combining DREADD technology, gene therapy, and tissue engineering. Theoretically this approach could be potentiated by CRISPR (clustered regularly interspaced short palindromic repeats) technology ([@CIT0010]). Thus, for instance, one could envision engineering iPSCs by knocking in DREADDs into the downstream regions of disease-related GPCR targets using CRISPR. DREADDs could then be expressed at physiologically relevant levels in the correct cellular context. Following transplantation, we could then remotely control engineered iPSCs by administrating CNO, a drug-like small molecule, to potentially cure human disease.

Other applications are equally obvious---e.g., by engineering endogenous muscarinic receptors via CRISPR technology one could create mice in which endogenous muscarinic receptors are replaced by DREADDs to achieve precise control over muscarinic receptor subtype signaling. This would allow researchers to deconstruct the roles of various muscarinic receptors in neuropsychiatric disease models. Alternatively, CRISPR-based technology could be used to knock-in DREADDs into essentially any locus in the genome to achieve cell-type specific control of signaling in virtually any tissue and organ. Indeed, with the currently available tissue engineering, gene therapy, and synthetic biology tools we are limited only by our imagination in how we might adapt DREADD technology for interrogating and ultimately treating human neuropsychiatric diseases.
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